Injury update: Texas A&M football could see sorely-needed contributor return soon
Texas A&M football could see top contributor make return to lineup for first time this season
Texas A&M football started off the year healthy coming into fall camp. But even before the first game against Notre Dame, the Aggies lost a big contributor.
RB Rueben Owens, set to take on a bigger role after a promising year one, suffered a foot injury that was reportedly set to sideline him for the season. Even though that was the original report, though, there were some whispers that the former five-star coudl return at some point in the season.
As the weeks have drug on, though, Owens has appeared repeatedly on the injury report as "Out." He, along with others like Mark Nabou and Tyreek Chappell who joined him, seemed destined to wait for their return into the offseason.
But now that the injury report for this week's Auburn game has come out, fans noticed something interesting on the list. Owens, rather than remain with the tragically-growing list of "Out"s, is listed as "Doubtful."
He and Chase Bisontis both received that designation, which indicates that they have a mere 25% chance, roughly, to play. Of course, that's 25% more than he has had all season, so that's something pretty big.
What would a return to the lineup for Owens mean to this Aggies team? It's hard to overstate it with the current state of the running back room. Amari Daniels is the top back right now, but there's not a lot behind him in the way of proven talent.
Owens has flashed a lot of potential for the Aggies in his snaps, and he earned well his five-star status in high school. That said, though, I am a bit worried about rust and lack of conditioning coming off of an injury like this—even so, though, the designation makes me think that he has been practicing at least a little bit.
If I had to guess, Owens will not play against Auburn—nor will Bisontis. I could be wrong, but I think we see them wait at least one more week. Maybe Owens still won't be ready by November 30, but this is still an encouraging sign.